score consisting of the mean of the responses to all the items. In the visual analog scale, participants rate their degree of itch on a 100-mm horizontal visual analog scale; possible scores range from 0 to 100, with a score of 0 indicating no itch and 100, extreme itch. Relevant clinical and demographic data were abstracted from electronic medical records. Pruritus was graded by following the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 5 Questionnaire responses and patient data were analyzed using SPSS, version 24 (IBM Corp); a 2-sided P < .05 was considered statistically significant.
Results | Seventy-nine patients evaluated by a dermatologist for pruritus attributed to immunotherapy were included; data were unavailable on pruritus grade, number of therapy cycles, and body distribution diagram for 2 patients. The mean (SD) age of patients was 63 (13) years, and 51 (65%) were male (Table) . The primary cancer diagnosis was genitourinary in 28 patients (35%), melanoma in 16 (20%), and gastrointestinal in 12 (15%). Twenty-five patients (32%) received a diagnosis of pruritus in normal-appearing skin, and 36 (46%) presented with The median patient-rated degree of itch was 72 (interquartile range, 47-82) of 100 on a visual analog scale. Forty-two of 77 patients presented within the first 6 cycles of therapy (range of cycles, 1-58). The most common sites of pruritus included the trunk, and the least affected sites included the plantar feet, anterior neck, and genitalia ( Figure) . There was no significant difference in demographic characteristics, number of therapy cycles before presentation, pruritus severity, or QOL between patients with pruritus alone and patients with a coexisting eruption.
Discussion | Pruritus related to immunotherapy is a frequent adverse event that is associated with lower patient QOL. Because the patients described herein were referred to an oncodermatology clinic, they likely represent patients with severe pruritus or pruritus that did not respond to oncologists' interventions. Accordingly, severe (CTCAE grade 3) pruritus was common, with a mean ItchyQoL score greater than that found in patients receiving hemodialysis who reported chronic itch (2.29 vs 2.00). 6 Immunotherapy-related pruritus has been described to involve the scalp, 2 but our survey suggests anatomical involvement of the torso and extremities, with relative sparing of the head, neck, and acral areas.
There was no significant difference in how pruritus affected QOL between patients with and without a skin eruption, suggesting that pruritus without an eruption deserves attention and treatment in order to maintain QOL.
Immunotherapy-related pruritus represents a substantial burden on QOL in patients with cancer who are referred to a dermatologist. It demands attention and treatment even in normal-appearing skin given its association with reduced QOL and its potential to limit consistent administration of immunotherapy. Additional research is warranted to develop rational, pruritus-specific therapies that do not interfere with the activity of immunotherapies. Most pruritic corresponds to a maximum frequency of 64% of patients. Least pruritic corresponds to a minimum frequency of 1% of patients. Frequencies are expressed as percentages of all patients who completed this assessment.
Letters

Demographics, Comorbid Conditions, and Outcomes of Patients With Nonuremic Calciphylaxis
Calciphylaxis (calcific uremic arteriolopathy) is a rare, potentially life-threatening condition in which vascular calcification produces ulcerative skin lesions. Calciphylaxis was first described in patients with end-stage renal disease receiving dialysis, with an annual incidence of 35 cases per 10 000 patients in the United States. 1 Calciphylaxis has also been observed in patients without renal disease, and the condition is termed nonuremic calciphylaxis (NUC). The most common underlying conditions associated with NUC are hyperparathyroidism, malignant neoplasm, alcoholic liver disease, and autoimmune disorders. 2 In addition, exposure to some medications, such as corticosteroids, may increase the risk of NUC, possibly by affecting the receptor activator of nuclear factor-κB, receptor activator of nuclear factor-κB ligand, or osteoprotegerin, which are involved in regulation of extraskeletal calcification. 3 With this knowledge, we sought to investigate the demographics, comorbid conditions, and outcomes of patients with NUC at the University of Washington hospitals and to compare this information with prior published findings.
Methods | We reviewed patients' electronic medical records at the University of Washington hospital system, searching for the term "calciphylaxis" in the body of a pathology report or diagnostic line from 2000 to 2017. The pathology reports and the patients' medical records were reviewed to determine if the pathology was consistent with calciphylaxis. Additionally, medical histories were reviewed to determine if the patients had renal disease to categorize the condition as uremic calciphylaxis or NUC. The University of Washington institutional review board approved this study. Patient written informed consent was not required.
Results | We identified 81 cases of calciphylaxis. Of these cases, 16 patients (20%) had NUC. The patients with NUC ranged in age from 22 to 87 years, and 15 of 16 patients (94%) were women. All patients had ulceration. Skin biopsy specimens tested positive for calciphylaxis in 10 of 16 patients. Results were equivocal in 6 biopsy specimens; however, a consulting dermatologist determined that the results from these specimens were compatible with calciphylaxis, and there was no other clear diagnosis based on pathology findings. In the group of patients with NUC, 8 (50%) had received warfarin, while 2 (13%) had been treated with heparin. Three patients (19%) had systemic lupus or antiphospholipid syndrome and were also receiving warfarin. Two patients (13%) had diabetes and 1 (6%) had secondary hyperparathyroidism (Table) .
The most common treatments initiated in the NUC cohort were intravenous sodium thiosulfate 3 times per week (63%, n = 10), cinacalcet (6%, n = 1), and antibiotics (50%, n = 8). At the time of our analysis, 75% of patients (n = 12) with NUC were alive, with survival ranging from 1 to 14 years after diagnosis. 
